Association of opioid fills with centers for disease control and prevention opioid guidelines and payer coverage policies: physician, insurance and geographic factors

• Published in: International journal of clinical pharmacy Vol. 44; no. 2; pp. 428 - 438
• Main Authors: Togun, Adeniyi T., Mandic, Pinar Karaca, Wurtz, Rebecca, Jeffery, Molly Moore, Beebe, Timothy
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.04.2022; Springer; Springer Nature B.V
• Subjects: Aged; Analgesics, Opioid - therapeutic use; Benzodiazepines; Benzodiazepines - therapeutic use; Centers for Disease Control and Prevention, U.S; Chronic pain; Disease control; Diseases; Drug Prescriptions; Drugstores; Evaluation; Evidence-based medicine; Geography; Humans; Insurance; Internal Medicine; Medicare; Medicine; Medicine & Public Health; Morphine; Narcotics; Opioids; Patients; Pharmacy; Physicians; Policy; Practice guidelines (Medicine); Practice Patterns, Physicians; Prescription writing; Primary care; Research Article; United States - epidemiology; United States; Insurance type and geography; Payer coverage change; Provider specialty; CDC opioid guidelines; Opioids
• ISSN: 2210-7703; 2210-7711; 2210-7711
• DOI: 10.1007/s11096-021-01360-w

Background The Centers for Disease Control and Prevention (CDC) issued guidelines and certain healthcare payers have made pharmacy coverage changes (PCC) focusing on regulating prescription opioids. Aim We evaluated differences in the rate of first-time opioid fills at doses ≥ 50 morphine milligram equivalents (MME)/day and first-time opioid fills with benzodiazepine fill overlap following the CDC guidelines and following a PCC between provider types, geographic locations, and insurance types. Method We used OptumLabs® Data Warehouse claims data between 2014 and 2018. Subjects were opioid naïve non-cancer care patients, 18 years and older who had an identified chronic pain condition ICD diagnosis within 2 weeks prior to their first-time opioid fill. We used multiple treatment period segmented regression analysis with interaction terms to test the differences between primary care providers (PCPs) and specialist providers (SPs), urban and rural primary care service areas (PCSAs), and Medicare Advantage (MA) and commercially insured patients (CIPs) in their first-time opioid fill patterns. Results Prescribing first-time opioid fills at doses ≥ 50MME/day declined following the CDC guidelines and PCC, the decline was greater among SPs than PCPs and in rural PCSAs than urban PCSAs. Also, following the CDC guidelines, the decline was greater among MA patients however following the PCC the decline was greater among CIPs. There were no differences in rate of first-time opioid fill with benzodiazepine overlap between groups. Conclusion Responses to the CDC opioid guidelines and a PCC differed between PCPs and SPs, urban and rural PCSAs, and when prescribing to MA and CIPs. Understanding these differences is important to help inform future guidelines.